Drug intelligence / Profile preview

EDP006

Development stage: Preclinical
Lead developer: Genor Biopharma
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

EDP006 is an investigational bispecific or multispecific antibody being developed by Genor Biopharma for the treatment of chronic respiratory diseases, specifically asthma and chronic obstructive pulmonary disease (COPD). As part of Genor Biopharma's antibody-based biologics pipeline, EDP006 is designed to target multiple pathways involved in airway inflammation or remodeling. While the specific molecular targets have not been publicly disclosed by the developer, the drug represents a multi-targeted therapeutic approach intended to address the complex pathophysiology of inflammatory lung conditions.

Beyond the preview

Go deeper on EDP006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDP006.

Explore the full profile